Learning and research

Skip to main content

User account menu

Join
Log in

Main navigation

Upcoming events
Learning and research
IDDI Workstreams & Task Forces
Membership
Pulmonary hypertension
Support us
About us

User account menu

Join
Log in

Breadcrumb

Home
Learning and Research

Pagination

Previous page
Page 10

Related content

GoDeep Global PH Registry
PVRI Digital Webinar Series
Pulmonary Circulation
Pulmonary Hypertension Global Patient Survey (PH GPS)
Latest news
Pulmonary Circulation Gateway Programme

Fulltext search

Reset filters

Fulltext search

Publication Types

Congresses & Symposia
- PVRI 2026 Dublin
  - Plenary talks
  - Satellite meetings
- PVRI 2025 DDDS
- PVRI 2025 Rio
- PVRI 2024 London
- PVRI 2023 DDDS
- PVRI 2022 Athens
Community Calls
Digital Webinar Series
- 2025/26 Cutting Edge
- 2025/26 Living Legend
- 2023/24 Series
- 2021/22 Series
IDDI Workstream or Task Force Learning
- Disease & Specialty Task Force
  - Exercise
  - High Altitude
  - Imaging
  - iPVD Consortium
  - Paediatric
  - PAH-ICON
  - PHGPS
  - Women's Health
- Regional Task Force
  - Central Asia
  - China
  - India
  - Latin America
  - SAPH
  - Sri Lanka
- Workstream
  - Access to Care
  - Challenges of Clinical Trial Design, Conduct & Endpoints
  - Lung Transplantation in PH
  - New Modalities & Technologies in PH & Right Heart Failure
  - Paediatric Clinical Trial Design & Endpoints
  - Patient Engagement & Empowerment
  - PH Group III
  - Real World Evidence/Data
Pulmonary Circulation

Subjects

Basic research and pathophysiology
- Cellular and molecular biology
- Genetics/genomics and other Omics
- Immunology and inflammation
- Infections and PVD
- Right ventricle
Diagnostic and assessment methods
- 1MWT, 6MWT, Incremental shuttle walk test
- Biomarkers
- Cardiopulmonary exercise test
- Genetic markers
- Hemodynamic assessments
- Imaging techniques
- Pulmonary function test
Diseases and clinical manifestations
- Group 1: Pulmonary Arterial Hypertension (PAH)
- Group 2: PH associated with left heart disease
- Group 3: PH associated with lung disease and/or hypoxia
- Group 4: PH associated with pulmonary artery obstruction / CTEPH
- Group 5: PH with unclear and/or multifactorial mechanisms
- Paediatric PH
- Exercise-induced PH
- Other lung disorders relevant to PH
- Related cardiovascular conditions
Emerging trends and future research
- Emerging therapies
- Novel clinical trial designs in PH
- Policy and guidelines
- Technological advances
Epidemiology and public health
- Global health and PH
- Incidence, prevalence, and risk factors
- Population studies and public health initiatives
Patient care and advocacy
- Advocacy and quality of life improvement
- Palliative care in PH
- Psychosocial aspects and patient education
- Special circumstances
- Symptom management
Treatment
- Perioperative care
- PH-specific therapies
- Special populations
- Supportive therapy
- Surgical and interventional procedures
Historical Vignette

10 February 2026

Sotatercept: from clinical trials to real world data & pearls from practice

Presented at PVRI 2026 Congress by Ioana Preston, Lahey Hospital & Medical Center

Congresses & Symposia

Pagination

First page First

Previous page Previous

…

Page 8

Page 9

Page 10

Current page 11

Footer Menu

GET LEARNING
- Attend an event
- Keep up with PVD developments
GET CONNECTED
GET INVOLVED

Follow us on LinkedIn
Follow us on X
Follow us on Bluesky

Footer menu - pages

Accessibility
AI commitment
Code of Conduct
Complaints
Cookies Policy
Diversity, Equity & Inclusion Policy
Privacy Policy
Social Media Policy
Terms & Conditions

The Pulmonary Vascular Research Institute (PVRI) is a charity registered in England & Wales no. 1127115 and a Company Limited by Guarantee no. 05780068. VAT registration no. 488 0247 66. Registered office: 5 Tanner Street, London SE1 3LE. Phone number: + 44 (0) 7934 126930.

Translate this page